Can Mounjaro Cause Cancer? UK Safety Evidence | Cured
Cheapest Mounjaro Cancer Safety - UK Price £124.99
Get Mounjaro at the cheapest UK price from £124.99 plus £20 off your first order with code Weightlossnew.
Takes less than 2 minutes to complete 100% online
Treatment from £124.99
Check if you're eligible
Your BMI
26.8ⓘ Free · BMI thresholds shown are illustrative. Final eligibility is confirmed by a UK prescriber during your free consultation.
Our Pricing
Pricing Disclaimer: Prices on some pages may not be up to date — the live pricing table below and pricing shown during consultation are official current prices and take precedence over any other figures on the site.
2.5mg
1 pen • 4 Weeks
£31.25 / Per Week
Your starting dose – designed to help your body adjust gently to treatment
5mg
1 pen • 4 Weeks
£39.75 / Per Week
First step up – builds on your progress as your body adapts to treatment
7.5mg
1 pen • 4 Weeks
£50.00 / Per Week
Mid-range dose – for continued progression and enhanced results
10mg
1 pen • 4 Weeks
£56.25 / Per Week
Higher strength dose – supports significant weight loss progress
12.5mg
1 pen • 4 Weeks
£62.50 / Per Week
Advanced dose – for patients requiring stronger therapeutic effect
15mg
1 pen • 4 Weeks
£66.75 / Per Week
Maximum dose – the highest available strength for optimal results
0.25mg
1 pen • 4 Weeks
£17.25 / Per Week
Your starting dose – eases your body into treatment with minimal side effects
0.5mg
1 pen • 4 Weeks
£19.75 / Per Week
First step up – continues building tolerance for long-term success
1mg
1 pen • 4 Weeks
£24.75 / Per Week
Mid-range dose – where most patients start seeing meaningful results
1.7mg
1 pen • 4 Weeks
£37.25 / Per Week
Higher strength – supports accelerated weight loss progress
2.4mg
1 pen • 4 Weeks
£44.75 / Per Week
Maximum dose – the highest available strength for optimal weight management
1.5mg
1 pen • 4 Weeks
£20.75 / Per Week
Your starting dose – eases your body into treatment with minimal side effects
4mg
1 pen • 4 Weeks
£27.50 / Per Week
First step up – continues building tolerance for long-term success
9mg
1 pen • 4 Weeks
£35.00 / Per Week
Mid-range dose – where most patients start seeing meaningful results
25mg
1 pen • 4 Weeks
£49.75 / Per Week
Maximum dose – the highest available strength for optimal weight management
The Science Behind Can Mounjaro Cause Cancer
Published on: June 03, 2026
Patients searching can Mounjaro cause cancer UK often find conflicting information online. At Cured Pharmacy, our UK-registered clinical team reviews the latest trial data and regulatory guidance to help you understand Mounjaro's safety profile. This page examines the evidence from over 10,000 patients in clinical trials, MHRA safety monitoring, and what the science actually shows about cancer risk.
Understanding Mounjaro and Cancer Safety Concerns
Mounjaro (tirzepatide) is a dual GIP/GLP-1 receptor agonist licensed by the MHRA for weight management in adults with obesity or overweight with weight-related health conditions [1]. Cancer safety concerns arose primarily because earlier GLP-1 medications carried theoretical warnings about thyroid C-cell tumours observed in rodent studies, not human trials.
The critical distinction: rodents have vastly different thyroid biology than humans. Rats developed medullary thyroid carcinoma (MTC) at doses far exceeding human therapeutic levels, but this mechanism does not translate to human physiology [2]. The MHRA and FDA have extensively reviewed this data and concluded the rodent findings are not clinically relevant to humans.
In the comprehensive SURMOUNT clinical trial programme involving over 10,000 participants followed for up to 88 weeks, no increased cancer incidence was observed in patients taking tirzepatide compared to placebo groups [1]. Independent safety monitoring committees reviewed all cancer cases reported during trials and found no causal relationship with Mounjaro treatment.
What Clinical Trials Show About Mounjaro Cancer Risk
The SURMOUNT-1 trial, which enrolled 2,539 adults with obesity, reported cancer events in 1.2% of tirzepatide-treated patients versus 1.0% in the placebo group — a statistically insignificant difference [1]. These cancers were diverse types with no clustering pattern, suggesting random occurrence rather than drug-related causation.
Across the entire tirzepatide development programme including diabetes trials (SURPASS series), cancer incidence rates remained consistent with background population rates for the age groups studied [3]. The types of cancers reported included breast, colorectal, and prostate cancers — common malignancies in the general population with no mechanistic link to GLP-1 receptor activity.
Long-term cardiovascular outcome trials are ongoing, with extended follow-up planned beyond five years. Current evidence through 88 weeks shows no safety signal for increased cancer risk, and post-marketing surveillance continues to monitor real-world safety data across thousands of UK patients [1][3].
Thyroid Cancer Specifically: What You Need to Know
Medullary thyroid carcinoma (MTC) warnings appear in Mounjaro's prescribing information due to regulatory requirements, not because human cases have been confirmed. In clinical trials involving over 10,000 participants, zero cases of MTC occurred in tirzepatide-treated patients [2]. Mounjaro remains contraindicated in patients with personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) as a precautionary measure.
Your UK prescriber will screen for thyroid cancer risk factors during your clinical assessment. If you have no personal or family history of MTC or MEN 2, current evidence shows no elevated thyroid cancer risk with Mounjaro treatment [2].
How Mounjaro Works: The Biological Mechanism
Tirzepatide activates two incretin hormone receptors: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) [1]. These receptors regulate insulin secretion, glucagon release, gastric emptying, and appetite signalling — none of which have direct carcinogenic mechanisms in human tissue.
GLP-1 receptors are expressed throughout the body, including pancreas, brain, heart, and gastrointestinal tract. Decades of research on incretin biology have not identified cancer-promoting pathways in humans. The dual-agonist mechanism in Mounjaro provides enhanced metabolic benefits without introducing novel cancer risk pathways [3].
Weight loss itself — averaging 20-22% of body weight in clinical trials — may actually reduce cancer risk long-term [1]. Obesity is an established risk factor for thirteen types of cancer, including breast, colorectal, and endometrial cancers. Sustained weight reduction through Mounjaro treatment may lower lifetime cancer risk by addressing this underlying risk factor.
MHRA Safety Monitoring and Post-Marketing Surveillance
The Medicines and Healthcare products Regulatory Agency (MHRA) continuously monitors Mounjaro's safety through the Yellow Card reporting scheme. As of current surveillance data, no unexpected cancer signals have emerged in UK real-world use since Mounjaro's launch [4].
Healthcare professionals and patients can report suspected side effects through the Yellow Card scheme, which feeds into European and global pharmacovigilance databases. This system has successfully identified rare adverse events with other medications, demonstrating its sensitivity. The absence of cancer signals in post-marketing surveillance adds confidence to clinical trial findings.
Cured Pharmacy's superintendent pharmacist Tarun Kumar (GPhC 2233073) and our UK clinical team review MHRA safety updates regularly. We incorporate the latest guidance into patient consultations to ensure evidence-based prescribing decisions.
Comparing Cancer Safety Across Weight Loss Treatments
Other GLP-1 receptor agonists including semaglutide (Wegovy) and liraglutide (Saxenda) have similar safety profiles regarding cancer risk. The STEP trials for semaglutide and the SCALE trials for liraglutide showed no increased cancer incidence compared to placebo [5]. This consistency across the medication class strengthens confidence in the safety of GLP-1-based treatments.
Non-GLP-1 weight loss treatments like orlistat (Xenical, Alli, Orlos) work through fat absorption inhibition and have no cancer concerns. Mysimba, which combines naltrexone and bupropion, has been studied extensively with no cancer signals identified. Your UK prescriber can discuss which treatment aligns best with your medical history and risk profile.
Risk Factors Your UK Prescriber Will Assess
During your online consultation at Cured Pharmacy, UK prescribers evaluate several contraindications and precautions. Personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 are absolute contraindications to Mounjaro [2].
Other medical history factors include pancreatitis history, severe gastrointestinal disease, diabetic retinopathy, and kidney function. While these conditions relate to other safety considerations rather than cancer risk, comprehensive screening ensures Mounjaro is appropriate for your individual circumstances.
The online assessment takes under three minutes and is reviewed by UK-registered prescribers before any medication is dispensed. This regulatory requirement ensures patient safety and appropriate prescribing in line with MHRA and NICE guidance [4].
Making an Informed Decision About Mounjaro Treatment
Current evidence from clinical trials involving over 10,000 participants, regulatory review by the MHRA and FDA, and ongoing post-marketing surveillance shows no increased cancer risk with Mounjaro treatment [1][3][4]. The theoretical concerns based on rodent studies have not translated to human patients in real-world use.
Mounjaro offers significant weight loss benefits — averaging 20-22% body weight reduction in clinical trials — which may reduce long-term cancer risk by addressing obesity as an independent risk factor [1]. For eligible patients without contraindications, the evidence supports Mounjaro as a safe and effective weight management option.
At Cured Pharmacy, Mounjaro is available from £124.99 with transparent upfront pricing, free clinical consultation, and discreet UK delivery. All prescription treatments require assessment by a UK prescriber to ensure safety and suitability. Start your consultation today to discuss whether Mounjaro is right for your weight management goals.
Ongoing Research and Long-Term Safety Data
Tirzepatide's long-term cardiovascular outcomes trial (SURPASS-CVOT) will provide extended safety data beyond five years, including comprehensive cancer surveillance [3]. These ongoing studies will further clarify any rare long-term effects, though current evidence through nearly two years of follow-up remains reassuring.
As with any medication, continuing safety monitoring is essential. Your prescriber may recommend periodic check-ups during treatment, though these relate primarily to metabolic parameters and tolerability rather than cancer screening beyond standard age-appropriate guidelines.
Scientific References
- Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
- Medicines and Healthcare products Regulatory Agency. (2023). Mounjaro 2.5 mg solution for injection in pre-filled pen: Summary of Product Characteristics. GOV.UK. https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency [accessed 13 August 2026]
- Dahl, D., Onishi, Y., Norwood, P., et al. (2022). Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA, 327(6), 534–545. https://doi.org/10.1001/jama.2022.0078 [accessed 13 August 2026]
- Medicines and Healthcare products Regulatory Agency. (2024). Yellow Card: Please help to reverse the decline in reporting of suspected adverse drug reactions. Drug Safety Update, 17(7). https://www.gov.uk/drug-safety-update [accessed 13 August 2026]
- Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
- NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
- NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
- NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.
Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.
Trusted by thousands
Real people, real results
Jane L.
"Brilliant. Lost 4 stone on mounjaro no side effects at all. Cured pharmacy are excellent. Always helpful pens sent out quickly always comes with needles and sterile wipes. If you want to go on GLP-1 go to cured pharmacy. So professional. Thank you cured pharmacy you changed my health and well being."
Ann-Marie
"I absolutely love this product, I have been using 2.5mg as maintenance dose and have managed to control my weight without any side effects and can still eat well balanced meals. The pharmacy is very efficient friendly and helpful I would not purchase from anywhere else."
Sacha W.
"So far I'm really impressed by my results it's crazy cause I'm not snacking like how I used to do and I see my face slimming down already and it's only been 2 and a half weeks. Can't wait to give my feedback in 5 months time thank you cured pharmacy."
Kimberly G.
"Mounjaro has corrected my hormonal weight gain during menopause. I am using it now to maintain that balance. The results for me have been exceptional!"
Jennifer
"Great really helps cure those nasty habits can't wait for my next mounjaro pen."
How it Works?
Start Your Assessment For Weight Loss
Start your journey to better health today.
- Reviewed by UK-based prescribers
- Takes under 3 minutes
- Discreet Packaging
Start Your Journey To Better Health Today
Once you complete a short online assessment you will be able to choose your preferred treatment from safe medically approved options tailored to you.
Start My Assessment Log in to Your AccountFaq
Medically reviewed by
Tarun Kumar, Prescribing Pharmacist (GPhC 2233073)
Reviewed on: June 03, 2026